Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Other

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury

By The Northwire Desk — AI Analysis Feb 09, 2026 · 07:00 NGEN · 5.35 Nervgen Pharma Corp.
NGEN · Price

Executive Summary

  • The Board of Directors appointed Dr. Adam Rogers as President and Chief Executive Officer, effective immediately.
  • Dr. Rogers’ appointment follows his successful interim tenure, during which the company completed its Nasdaq listing and advanced NVG‑291 toward late‑stage development.
  • Concurrent with the appointment, the Company granted Dr. Rogers 717,891 stock options at exercise prices of US $5.06 (614,799 options) and US $5.57 (103,092 options), vesting over four years.

Key Details

  • Appointment: Adam Rogers, MD – previously Interim CEO and Board member since July 2022 – is now President & CEO.
  • Rationale: Board cited his “decisive execution against key milestones,” including the Nasdaq listing and progress of NVG‑291.
  • Option Grant:
  • Total options granted: 717,891.
  • Vesting schedule: 25 % on first anniversary; remaining 75 % in equal monthly installments over the next 36 months, contingent on continued service.
  • Exercise prices & terms:
    • 614,799 options at US $5.06 per share, exercisable for ten years from grant date.
    • 103,092 options at US $5.57 per share, exercisable for five years from grant date.
  • Company Context: NervGen is a clinical‑stage biopharma developing NVG‑291 (neuroreparative peptide) for spinal cord injury; the candidate has Fast Track (FDA) and Orphan Drug (EMA) designations and is moving toward Phase 3 trials.
  • Leadership Background: Dr. Rogers is a board‑certified ophthalmologist, principal at PFP Biosciences Holdings, co‑founder of Hemera Biosciences (acquired by Janssen), and former Assistant Professor of Ophthalmology at Tufts Medical Center.

Notable Quotes

  • Craig Thompson, Independent Director: “Adam exemplifies the leadership qualities that NervGen requires…bringing the unique perspective of a practicing physician and seasoned biotech executive.”
  • Adam Rogers, MD, CEO: “We are at a point in the Company’s growth where focus, discipline, and execution matter more than ever…”
Read the original news release →

More from Nervgen Pharma Corp.

Apr 07, 2026 · 07:30

FDA aligns on Phase 3 design, clearing the path for NVG‑291’s registrational trial

Other Mar 31, 2026 · 07:45

Clinical Validation Confirmed, Capital Runway Tightens Ahead of Phase 3 Pivot

Earnings Mar 12, 2026 · 16:15

NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange

Financings Jan 08, 2026 · 06:30

NervGen Pharma Begins Trading on Nasdaq Today

Regulatory Nov 24, 2025 · 07:06

NervGen Pharma Reports Third Quarter Financial Results and Provides Business Updates

Earnings Nov 24, 2025 · 07:02

NervGen Pharma Announces Expanded CONNECT SCI Study Data Demonstrating Unprecedented Durable Improvement in Function, Independence, and Quality of Life in Chronic Spinal Cord Injury

Other